- The enhancement use of neuropharmaceuticals: more scepticism and caution needed, Hall W.D., Lucke J.C., p. 2041-2043.
- Sun-downing and integration for the advancement of science and therapeutics: the National Institute on Substance Use Disorders (NISUD), Grabowski J., p. 2044-2049. 5 commentaries.
- Addiction research centres and the nurturing of creativitydepartment of addictive behaviour and addiction medicine, central institute of Mental Health, Mannheim, University of Heidelberg, Mann K., p. 2057-2061.
- The global diversion of pharmaceutical drugsnon-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures, Fischer B., Bibby M., Bouchard M., p. 2062-2070.
- Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis, Cleary B.J., Donnelly J., Strawbridge J., Gallagher P.J., Fahey T., Clarke M., et al., p. 2071-2084.
- Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing, Teesson M., Hall W., Slade T., Mills K., Grove R., Mewton L., et al., p. 2085-2094 + commentary.
- Harsh physical punishment as a specific childhood adversity linked to adult drinking consequences: evidence from China, Cheng H.G., Anthony J.C., Huang Y., p. 2097-2105.
- Change talk sequence during brief motivational intervention, towards or away from drinking, Bertholet N., Faouzi M., Gmel G., Gaume J., Daeppen J.B., p. 2106-2112.
- Potential consequences of replacing a retail alcohol monopoly with a private licence system: results from Sweden, Norstrom T., Miller T., Holder H., Osterberg E., Ramstedt M., Rossow I., et al., p. 2113-2119.
- Quality versus quantity: acquisition of coping skills following computerized cognitive-behavioral therapy for substance use disorders, Kiluk B.D., Nich C., Babuscio T., Carroll K.M., p. 2120-2127 + Commentary.
- Victimization and substance use disorders in a national sample of heterosexual and sexual minority women and men, Hughes T., Mccabe S.E., Wilsnack S.C., West B.T., Boyd C.J., p. 2130-2140.
- The self-reported personal wellbeing of a sample of Australian injecting drug users, Dietze P., Stoove M., Miller P., Kinner S., Bruno R., Alati R., et al., p. 2141-2148 + Commentary.
- Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome, Gray T.R., Choo R.E., Concheiro M., Williams E., Elko A., Jansson L.M., et al., p. 2151-2159.
- Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study, Carrieri M.P., Roux P., Cohen J., Ravaux I., Dellamonica P., Protopopescu C., et al., p. 2160-2168.
- Pathological gambling recovery in the absence of abstinence, Slutske W.S., Piasecki T.M., Blaszczynski A., Martin N.G., p. 2169-2175.
- Impulsivity and socio-economic status interact to increase the risk of gambling onset among youth, Auger N., Lo E., Cantinotti M., O'loughlin J., p. 2176-2183.
- A comparison of four international surveys of tobacco dependence treatment provision: implications for monitoring the Framework Convention on Tobacco Control, Bitton A., Raw M., Richards A., Mcneill A., Rigotti N.A., p. 2184-2191 + Commentary.
- A multi-level analysis of non-significant counseling effects in a randomized smoking cessation trial, Mccarthy D.E., Piasecki T.M., Jorenby D.E., Lawrence D.L., Shiffman S., Baker T.B., p. 2195-2208.
- Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day, Berlin I., Chen H., Covey L.S., p. 2209-2216.
- Industry funding and placebo quit rate in clinical trials of nicotine replacement therapy: a commentary on Etter et al. (2007), Greene N.M., Taylor E.M., Gage S.H., Munafo M.R., p. 2217-2218; author reply 2219.
- Innovative but insufficient? A response to graham's commentary on 'alcohol, suppressed anger and violence', Norstrom T., Pape H., p. 2219-2220.